Table 1 Characteristics of the included studies
First author | Year | Study Year of recruitment | Country | Study design | Age, y | Tumor stage N(%) | LNM N(%) | CRP threshold (mg/L) | No. of Subjects/Cases | Outcome assessment | Hs-CRP/CRP | HR(95%Cl) | Quality scores |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Steffens, S. [13] | 2013 | 1990–2010 | Germany | PC | 65.4(33–92) | ≥T2:36 (45.6%) | 16 (25%) | 15 | 79/34 (43%) | Institution | CRP | 5.58(1.79 ~ 17.42) | 8 |
Li, Z.S. [16] | 2016 | 2007–2014 | China | PC | 50(25–86) | T2:68 (54.8%) ≥T3:14 (11.3%) | 60 (48.4%) | 4.5 | 124/54 (43%) | Institution | CRP | 8.416(0.976 ~ 72.583) | 8 |
Li, Z. [17] | 2016 | 2005–2014 | China | PC | 52 (25–86) | ≤T1:57(33.1%); T2:90(52.3%); ≥T3:25(14.5%) | 84 (48.8%) | 8.7 | 172/59 (34.3%) | Institution | CRP | 3.706(1.531–8.972) | 8 |
Ghoshal, A. [14] | 2017 | Not given | Sweden | PC | 51(10.6) | Not given | Not given | 10 | 50/8(12%) | Laboratory examinations | CRP | 0.59(0.25 ~ 1.41) | 7 |
Zhou, Q. [18] | 2018 | 2009–2015 | China | PC | 54 | T2-4:77 (97.5%) | 47 (59.5%) | 5.0 | 79/22(28%) | UCC | CRP | 2.465(1.064 ~ 5.712) | 7 |
Draeger, D. [2] | 2021 | 2005–2019 | Germany | PC | 65.4 (13.8) | T2:107 (69%) T3:43 (28%) T4:6 (4%) | All;100% | 10 | 156/74(47%) | Department | CRP | 1.66(1.11 ~ 2.53) | 8 |
Kawase, M. [19] | 2022 | 2008–2019 | Japan | PC | 74 (63–82) | Tis:1(1.6%); T1: 21(32.8); T2:14(21.9%); T3:17(26.6%); T4: 11(17.2%) | 26 (40.7%) | 2.1 | 58/28 (48%) | Department | CRP | 3.536 (0.86–14.52) | 7 |
Xue, T. [20] | 2023 | 2006–2021 | China | PC | 55 | T1:100(36.9%);T2:44(16.2%);T3:115(42.4%);T4:12(4.4%) | 104(38.3%) | 10 | 271/56 (20.7%) | Department | CRP | 2.77(1.36–5.64) | 8 |